AZN
AstraZeneca PLC
$66.57
Earnings Summary
Revenue | $5155Mn |
Net Profits | $350Mn |
Net Profit Margins | 6.79% |
Highlights
AstraZeneca PLC’s revenue jumped 2.06% since last year same period to $5155Mn in the Q2 2018. On a quarterly growth basis, AstraZeneca PLC has generated -0.44% fall in its revenue since last 3-months.
AstraZeneca PLC’s net profit fell -26.62% since last year same period to $350Mn in the Q2 2018. On a quarterly growth basis, AstraZeneca PLC has generated 2.94% jump in its net profits since last 3-months.
AstraZeneca PLC’s net profit margin fell -28.11% since last year same period to 6.79% in the Q2 2018. On a quarterly growth basis, AstraZeneca PLC has generated 3.4% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the AstraZeneca PLC post its latest quarter earnings
EPS Estimate Current Quarter | 0.88 |
EPS Estimate Current Year | 0.88 |
Highlights
AstraZeneca PLC’s earning per share (EPS) estimates for the current quarter stand at 0.88 - a 23.27% jump from last quarter’s estimates.
AstraZeneca PLC’s earning per share (EPS) estimates for the current year stand at 0.88.
Key Ratios
Key ratios of the AstraZeneca PLC post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Dividend Per Share (DPS) | 0.99 |
Highlights
AstraZeneca PLC’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the AstraZeneca PLC has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
AstraZeneca PLC declared 0.99 dividend per share during the earnings announcement for Q1 2023.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2017-06-30 | 0.42 | 0.44 | 4.76% |
2017-12-31 | 0.47 | 0.65 | 38.3% |
2017-03-31 | 0.4 | 0.5 | 25% |
2017-09-30 | 0.55 | 0.56 | 1.82% |
Company Information
AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca plc - ADR has a market cap of $202.1 Billion. It has a P.E ratio of 61.46. The shares of Astrazeneca plc - ADR are trading at $66.99. .
Organisation | AstraZeneca PLC |
Headquarters | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
Employees | 83500 |
Industry | Health Technology |
CEO | Pascal Soriot |
